MEDICAL DISCLAIMER: This information is intended for educational purposes only and should not be considered medical advice. It is designed to provide comprehensive, evidence-based medical knowledge for healthcare professionals. Clinical decisions must always be made in the context of the individual patient, their specific circumstances, available resources, and the clinician's best judgment. Always refer to the most current guidelines and consult with specialists when necessary. This content does not substitute for professional medical advice, diagnosis, or treatment.

---

Viral Hepatitis

Overview

• Definition: Viral hepatitis is an inflammation of the liver caused by one of several distinct hepatotropic viruses, primarily hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis D virus (HDV), and hepatitis E virus (HEV). These infections can range from asymptomatic, self-limited acute illness to chronic, life-threatening conditions such as cirrhosis and hepatocellular carcinoma (HCC).
• Epidemiology:
  • Global Burden: Hepatitis B and C are major global health problems, affecting hundreds of millions of people and causing over 1 million deaths per year.
  • Hepatitis A: Primarily transmitted via the fecal-oral route. Common in regions with poor sanitation. Vaccine-preventable. Incidence has decreased significantly in countries with routine childhood vaccination programs.
  • Hepatitis B: Over 250 million people chronically infected worldwide. Endemic in many parts of Asia and Africa. Transmitted parenterally (blood, sexual, perinatal). Major cause of cirrhosis and HCC.
  • Hepatitis C: Approximately 71 million people chronically infected worldwide. Primarily blood-borne transmission (IV drug use, contaminated blood products before 1992, healthcare exposures). Leading cause of liver transplantation and HCC in many developed countries.
  • Hepatitis D: Requires co-infection with HBV; dependent on HBsAg for replication. Most prevalent in Mediterranean, Middle East, and parts of South America.
  • Hepatitis E: Fecal-oral transmission, often through contaminated water. Common in developing countries. Genotype 3 and 4 can cause chronic infection in immunocompromised individuals.
• Classification:
  • Hepatitis A Virus (HAV): Non-enveloped, single-stranded RNA virus. Causes acute hepatitis only; no chronic form.
  • Hepatitis B Virus (HBV): Enveloped, partially double-stranded DNA virus. Can cause acute and chronic hepatitis.
  • Hepatitis C Virus (HCV): Enveloped, single-stranded RNA virus. Can cause acute and chronic hepatitis. Highly prone to chronicity (75-85% of acute infections).
  • Hepatitis D Virus (HDV): Defective single-stranded RNA virus. Requires HBV co-infection. Can cause co-infection (simultaneous HBV/HDV) or superinfection (HDV on chronic HBV).
  • Hepatitis E Virus (HEV): Non-enveloped, single-stranded RNA virus. Causes acute hepatitis; chronic infection rare, primarily in immunocompromised hosts (e.g., organ transplant recipients).

Pathophysiology

• Mechanism:
  • Viral Replication: Hepatitis viruses primarily target hepatocytes. They replicate within these cells, using host cellular machinery.
  • Host Immune Response: Liver damage is largely mediated by the host immune response (cytotoxic T lymphocytes, NK cells) directed against viral antigens expressed on infected hepatocytes. This immune-mediated inflammation leads to hepatocyte necrosis, apoptosis, and regeneration.
  • Acute vs. Chronic: In acute infection, a robust and effective immune response clears the virus. In chronic infection, the immune response is insufficient or tolerant, leading to persistent viral replication and ongoing inflammation, which can progress to fibrosis, cirrhosis, and HCC over decades.
• Risk Factors:
  • HAV/HEV:
    • Consumption of contaminated food (e.g., raw shellfish) or water.
    • Close personal contact with an infected individual (e.g., household contacts, sexual contacts).
    • Travel to endemic areas.
    • Poor sanitation and hygiene.
  • HBV/HCV/HDV:
    • Parenteral Exposure:
      • Intravenous drug use (sharing needles, syringes, drug preparation equipment).
      • Transfusion of unscreened blood or blood products (historically, largely eliminated in developed countries since 1992).
      • Unsafe medical procedures (e.g., inadequate sterilization of medical equipment, unsafe injections).
      • Needle-stick injuries in healthcare settings.
    • Sexual Contact: Unprotected sexual intercourse (especially for HBV; less efficient for HCV). Multiple partners, history of STIs.
    • Perinatal Transmission: From an infected mother to her infant during birth (most common route for chronic HBV acquisition worldwide).
    • Household Contact: Sharing personal items contaminated with blood (razors, toothbrushes) (less common than other routes).
    • Tattooing/Piercing: Unlicensed or unsterile practices.
    • HBV-specific: Unvaccinated individuals, hemodialysis patients, inmates.
    • HCV-specific: HIV co-infection.
• Protective Factors:
  • Vaccination: Available and highly effective for HAV and HBV.
  • Safe Sex Practices: Consistent and correct use of condoms.
  • Harm Reduction Strategies: Needle exchange programs, safe injection sites for IV drug users.
  • Blood Product Screening: Universal screening of blood and organ donations.
  • Universal Precautions: In healthcare settings (e.g., proper use of PPE, safe handling of sharps).
  • Improved Sanitation and Hygiene: For HAV and HEV (e.g., safe drinking water, handwashing).
  • Perinatal Prophylaxis: Immunoprophylaxis and antiviral treatment for HBV-infected pregnant mothers to prevent vertical transmission.

Clinical Presentation

Signs and Symptoms

Clinical presentation varies significantly depending on the virus, acuity, and host immune response. Many acute infections, particularly in children, are asymptomatic. Chronic infections are often asymptomatic until advanced liver disease develops.

• Cardinal Features (Acute Hepatitis - Icteric Phase):
  • Jaundice: Yellowing of skin, sclera, and mucous membranes due to hyperbilirubinemia. Often the most prominent sign.
  • Dark Urine: Due to conjugated bilirubin in urine.
  • Pale/Acholic Stools: Due to decreased bilirubin excretion into the gut.
  • Fatigue/Malaise: Profound tiredness.
  • Nausea and Vomiting: Gastrointestinal distress.
  • Right Upper Quadrant (RUQ) Pain: Due to liver inflammation and swelling.
  • Anorexia: Loss of appetite.
• Early Signs (Prodromal Phase):
  • Fever (often low-grade, more common in HAV)
  • Fatigue, malaise
  • Anorexia, nausea, vomiting
  • Myalgia, arthralgia (joint pain)
  • Headache
  • Urticaria or rash (less common)
  • RUQ discomfort
• Advanced Signs (Chronic Hepatitis leading to Cirrhosis/Decompensation):
  • Fatigue, Weakness: Persistent and debilitating.
  • Pruritus: Itching due to bile salt deposition.
  • Edema: Peripheral edema, ascites (fluid accumulation in abdomen).
  • Bleeding/Bruising: Due to coagulopathy (decreased synthesis of clotting factors).
  • Confusion/Encephalopathy: Hepatic encephalopathy (altered mental status due to accumulation of toxins).
  • Asterixis: "Liver flap" (tremor of the hand when wrist is extended).
  • Gastrointestinal Bleeding: From esophageal varices.
  • Weight Loss: Unexplained.
  • Spider Angiomata: Vascular lesions resembling spiders.
  • Palmar Erythema: Redness of palms.
  • Gynecomastia/Testicular Atrophy: In males, due to hormonal imbalances.
• Atypical Presentations:
  • Anicteric Hepatitis: Acute hepatitis without jaundice (common, especially in children and for HEV/HAV).
  • Fulminant Hepatitis: Rare but life-threatening acute liver failure with encephalopathy and coagulopathy, often occurring within 8 weeks of symptom onset. More common with HBV superinfection with HDV, or severe HAV/HEV.
  • Cholestatic Hepatitis: Prolonged jaundice with significant pruritus, and elevated alkaline phosphatase, resembling biliary obstruction. More common in HAV and HEV.
  • Extrahepatic Manifestations: Immune-complex mediated phenomena, more common in chronic HBV and HCV.
    • HBV: Polyarteritis nodosa, glomerulonephritis, cryoglobulinemia (rarely).
    • HCV: Mixed cryoglobulinemia (with associated vasculitis, glomerulonephritis, neuropathy), porphyria cutanea tarda, lichen planus, Sjögren's syndrome, non-Hodgkin lymphoma.

Physical Examination

• Inspection:
  • Skin/Sclera: Jaundice (yellow discoloration).
  • Skin: Spider angiomata, palmar erythema, scratch marks (from pruritus).
  • Abdomen: Ascites (distension, fluid wave), dilated abdominal veins (caput medusae).
  • Extremities: Peripheral edema (pitting edema in ankles/legs), muscle wasting.
  • General: Cachexia, signs of malnutrition.
• Palpation:
  • Liver: Hepatomegaly (enlarged liver), tenderness in RUQ. In cirrhosis, liver may be small and nodular.
  • Spleen: Splenomegaly (due to portal hypertension).
  • Lymph Nodes: Generalized lymphadenopathy (less common, usually absent).
• Special Tests:
  • Asterixis: Ask patient to extend arms with wrists hyperextended; rapid, non-rhythmic flapping movements of dorsiflexed hands. Indicates hepatic encephalopathy.
  • Fluid Wave/Shifting Dullness: Techniques to assess for ascites.
  • Spider Angiomata Blanching: Apply pressure to the central arteriole; the lesion blanches and refills from the center outwards.

Diagnostic Approach

History Taking

• Key Questions:
  • Symptoms: Onset, duration, severity of fatigue, nausea, vomiting, abdominal pain, dark urine, pale stools, jaundice, itching.
  • Risk Factors/Exposures (Past 6 months - 6 years):
    • Travel History: To endemic areas (HAV, HEV).
    • Sexual History: Number of partners, unprotected sex, history of STIs.
    • Drug Use: IV drug use (ever, shared needles), intranasal drug use.
    • Blood/Body Fluid Exposure: Blood transfusions (especially pre-1992), organ transplantation, needle stick injuries, unsafe injections, occupational exposure.
    • Household Contacts: Exposure to jaundiced individuals, known hepatitis patients.
    • Medical Procedures: Surgery, endoscopy, hemodialysis, tattooing, body piercing (unsterile conditions).
    • Vaccination Status: HAV, HBV.
    • Alcohol Intake: Amount, frequency, duration (rule out alcoholic hepatitis).
    • Medication History: Over-the-counter, prescription, herbal supplements (rule out drug-induced liver injury).
    • Comorbidities: HIV, other autoimmune diseases.
  • Family History: Liver disease, hepatitis.
• Red Flags:
  • Signs of Decompensated Liver Disease: Jaundice, ascites, encephalopathy, coagulopathy, GI bleeding. Requires urgent hospitalization.
  • Sudden onset of severe symptoms with mental status changes: Suggests fulminant hepatic failure.
  • High-risk exposures in an unvaccinated individual: Warrants post-exposure prophylaxis consideration.

Laboratory Tests

Laboratory evaluation is essential for diagnosis, staging, and monitoring.

• First-Line (Initial Diagnostic Tests):
  • Liver Function Tests (LFTs):
    • Aminotransferases (AST, ALT): Typically significantly elevated (hundreds to thousands IU/L) in acute hepatitis. ALT often higher than AST. In chronic hepatitis, elevations may be milder or fluctuate.
    • Alkaline Phosphatase (ALP): Usually mildly elevated; marked elevation suggests cholestasis or biliary obstruction.
    • Total and Direct Bilirubin: Elevated in jaundice (conjugated hyperbilirubinemia).
    • Albumin: Normal in acute; decreased in chronic severe liver disease.
    • Prothrombin Time (PT)/INR: Prolonged in severe acute hepatitis and chronic liver disease due to impaired synthesis of clotting factors. Most important prognostic indicator in acute liver failure.
  • Hepatitis Serology (Acute Presentation):
    • Hepatitis A: Anti-HAV IgM (acute infection), Anti-HAV IgG (past infection/immunity).
    • Hepatitis B:
      • HBsAg: Hepatitis B surface antigen (indicates active infection, acute or chronic).
      • Anti-HBc IgM: Antibody to hepatitis B core antigen, IgM class (indicates acute or recent infection).
      • Anti-HBc Total (IgG + IgM): Total antibody to hepatitis B core antigen (indicates current or past infection).
      • Anti-HBs: Antibody to hepatitis B surface antigen (indicates immunity from vaccination or past infection).
    • Hepatitis C: Anti-HCV antibody (screening for exposure/infection). Positive requires confirmatory RNA testing.
    • Hepatitis D: Anti-HDV antibody (requires positive HBsAg for testing). HDV RNA (for active replication).
    • Hepatitis E: Anti-HEV IgM (acute infection), Anti-HEV IgG (past infection/immunity).
• Confirmatory (Definitive Diagnostic Tests):
  • Viral Nucleic Acid Testing (NAT) / PCR:
    • HBV DNA: Quantifies viral load, confirms active HBV replication, indicates need for treatment, and monitors response.
    • HCV RNA: Quantifies viral load, confirms active HCV infection (necessary after positive anti-HCV), indicates need for treatment, and monitors response (sustained virologic response - SVR). Genotyping determines HCV genotype for treatment selection (though less critical with pangenotypic DAAs).
    • HDV RNA: Confirms active HDV replication.
    • HEV RNA: For immunocompromised or atypical cases, especially for chronic HEV.
  • Liver Biopsy: Historically used for staging fibrosis and grading inflammation. Largely replaced by non-invasive tests for routine assessment. Still indicated for diagnostic dilemmas (e.g., unexplained LFT abnormalities, suspected autoimmune hepatitis, or extent of damage when non-invasive tests are inconclusive).
• Monitoring (Follow-up Tests for Chronic Hepatitis):
  • HBV:
    • HBsAg, HBeAg, Anti-HBe: Every 6-12 months for inactive carriers or treated patients to monitor for seroconversion or reactivation.
    • HBV DNA: Every 6-12 months, or more frequently if on treatment or during immune active phases.
    • ALT: Every 3-6 months initially, then every 6-12 months.
    • AFP (Alpha-fetoprotein): Every 6-12 months for HCC surveillance in at-risk patients (cirrhosis, Asian males >40, Asian females >50, family history of HCC, African-Americans >20).
  • HCV:
    • HCV RNA (Qualitative or Quantitative): For diagnosis, pre-treatment baseline, and to confirm Sustained Virologic Response (SVR) 12 weeks after treatment completion (SVR12).
    • LFTs: As needed, especially during and after treatment.
    • AFP: Every 6-12 months for HCC surveillance if cirrhosis is present.
  • Non-invasive Fibrosis Assessment:
    • FibroScan (Transient Elastography): Measures liver stiffness, correlating with fibrosis stage (F0-F4). Non-invasive, widely used.
    • Serum Biomarkers: APRI (AST to Platelet Ratio Index), FIB-4 (Fibrosis-4 score). These are calculated from routine lab tests and can estimate fibrosis stage. Useful for screening and identifying those who need further evaluation.

Imaging

• Recommended (Standard Imaging Studies):
  • Abdominal Ultrasound (US):
    • Initial Evaluation: To assess liver size, echotexture, exclude biliary obstruction, or detect focal lesions.
    • HCC Surveillance: For patients with cirrhosis or other high-risk factors (HBV carriers with advanced fibrosis/cirrhosis, or other risk criteria). Performed every 6 months.
• Advanced (Specialized Imaging when needed):
  • CT Scan / MRI of Abdomen with Contrast:
    • Characterization of Focal Liver Lesions: If US reveals a suspicious nodule during HCC surveillance.
    • Assessment of Cirrhosis Complications: Portal hypertension, varices, ascites, or to better define liver morphology.
    • Pre-transplant Evaluation: Detailed assessment of liver and vascular anatomy.
  • MRI Elastography (MRE): More accurate than transient elastography for assessing liver stiffness/fibrosis, especially in obese patients or with ascites, but less widely available and more expensive.

Management

Acute Management

Acute viral hepatitis (especially HAV, HEV) is usually self-limited and managed supportively. Severe cases or certain viral types (HBV, HCV in specific circumstances) may require specific interventions.

• Immediate:
  • Rest: Avoid strenuous activity during acute phase.
  • Hydration: Ensure adequate fluid intake, especially if vomiting.
  • Nutritional Support: Small, frequent meals; high-calorie, high-protein diet as tolerated. Avoid alcohol.
  • Discontinuation of Hepatotoxic Agents: Review and discontinue unnecessary medications/supplements.
  • Isolation Precautions: For HAV/HEV, standard infection control measures (hand hygiene). For HBV/HCV, blood and body fluid precautions.
• Stabilization:
  • Monitor for Signs of Fulminant Hepatic Failure:
    • Daily PT/INR and bilirubin.
    • Monitor mental status (Glasgow Coma Scale, ammonia levels if indicated).
    • Electrolyte monitoring.
  • Hospitalization: Indicated for severe symptoms (intractable vomiting, dehydration), signs of coagulopathy (INR >1.5), encephalopathy, or significant clinical deterioration.
• Emergency (Fulminant Hepatic Failure - FHF):
  • Intensive Care Unit (ICU) Admission: For close monitoring and management of multi-organ failure.
  • Aggressive Supportive Care:
    • Cerebral Edema Management: Mannitol, hypertonic saline, head elevation, hyperventilation.
    • Coagulopathy Correction: Vitamin K (if deficient), fresh frozen plasma (FFP) for active bleeding or before invasive procedures.
    • Renal Failure Management: Renal replacement therapy if needed.
    • Infection Prophylaxis/Treatment: Broad-spectrum antibiotics if fever/signs of infection.
    • Glucose Monitoring: Hypoglycemia common.
  • Antiviral Therapy:
    • HBV-associated FHF: Early initiation of nucleos(t)ide analogues (e.g., Entecavir, Tenofovir) is recommended, though data on efficacy for FHF is mixed.
    • HCV-associated FHF: Rare; no specific antiviral therapy recommended for acute HCV unless persistent.
  • Liver Transplantation: Urgent evaluation for liver transplant is crucial for patients with FHF who do not show signs of recovery. MELD score >30 or specific criteria (King's College, Clichy) are often used to prioritize.

Chronic Management

Management varies significantly by virus, disease activity, and fibrosis stage.

• Pharmacological:
  • Chronic Hepatitis B (CHB):
    • Goal: Suppress HBV DNA replication, prevent progression to cirrhosis, HCC, and improve long-term outcomes. Cure is rare, so treatment is often long-term.
    • Indications for Treatment (AASLD/EASL Guidelines):
      • Cirrhosis (compensated or decompensated) regardless of HBV DNA or ALT.
      • HBV DNA >2,000 IU/mL AND elevated ALT (>ULN) AND/OR moderate-to-severe inflammation/fibrosis on biopsy/elastography.
      • HBeAg-positive chronic hepatitis with HBV DNA >20,000 IU/mL AND elevated ALT (regardless of fibrosis).
      • HBV DNA >200,000 IU/mL and ALT >2xULN (for HBeAg positive).
      • Special populations: HIV co-infection, immunosuppressive therapy, HCC family history.
    • First-line Agents (Nucleos(t)ide Analogs - NUCs):
      • Entecavir (ETV): 0.5 mg orally once daily (1 mg for lamivudine-refractory). Potent, high barrier to resistance.
      • Tenofovir Disoproxil Fumarate (TDF): 300 mg orally once daily. Potent, high barrier to resistance. Monitor renal function and bone density.
      • Tenofovir Alafenamide (TAF): 25 mg orally once daily. Newer pro-drug of tenofovir with improved renal and bone safety profile compared to TDF.
    • Duration: Typically indefinite, or until HBsAg seroclearance (rare) or significant decline in liver disease with sustained undetectable HBV DNA.
  • Chronic Hepatitis C (CHC):
    • Goal: Achieve Sustained Virologic Response (SVR), which is considered a virologic cure (undetectable HCV RNA 12 weeks post-treatment). SVR leads to significant reduction in liver inflammation, fibrosis regression, and decreased risk of cirrhosis, HCC, and liver-related mortality.
    • Indications for Treatment: All HCV-infected patients should be considered for treatment, except those with short life expectancies unrelated to liver disease.
    • First-line Agents (Direct-Acting Antivirals - DAAs):
      • Pangenotypic Regimens: Highly effective across all HCV genotypes, simpler to prescribe. Examples:
        • Glecaprevir/Pibrentasvir (Mavyret): 300mg/120mg (3 tablets) orally once daily with food for 8 weeks (treatment-naïve, non-cirrhotic). Longer durations for cirrhotic or treatment-experienced patients.
        • Sofosbuvir/Velpatasvir (Epclusa): 400mg/100mg orally once daily for 12 weeks (treatment-naïve, compensated or decompensated cirrhosis).
      • Other Regimens: Ledipasvir/Sofosbuvir (Harvoni), Sofosbuvir/Daclatasvir, etc. (often genotype-specific or for specific populations).
    • Duration: Typically 8-12 weeks, depending on the regimen, genotype, cirrhosis status, and treatment history.
    • Efficacy: SVR rates exceed 95% for most DAA regimens.
• Non-pharmacological:
  • Alcohol Abstinence: Crucial for all forms of chronic hepatitis to prevent accelerated liver damage.
  • Healthy Diet and Lifestyle: Maintain a healthy weight, manage diabetes, control hyperlipidemia to prevent non-alcoholic fatty liver disease (NAFLD)/NASH as a co-factor for liver injury.
  • Avoid Hepatotoxic Substances: Illicit drugs, certain herbal supplements, excessive acetaminophen.
  • Vaccinations: Ensure vaccination against HAV and HBV in susceptible individuals to prevent co-infection or superinfection, which can worsen liver disease.
  • Regular Exercise: Improves general health and can help manage metabolic risk factors.
• Monitoring (Long-term Follow-up):
  • For all Chronic Hepatitis Patients:
    • Regular clinical assessment for signs of decompensation.
    • Liver function tests (ALT, AST, bilirubin, albumin, INR) every 6-12 months.
    • Fibrosis assessment (FibroScan, FIB-4) every 1-2 years if not cirrhotic.
  • Cirrhosis Surveillance:
    • HCC Surveillance: Semiannual (every 6 months) abdominal ultrasound +/- AFP for all cirrhotic patients (regardless of etiology), and selected high-risk non-cirrhotic HBV patients.
    • Esophageal Varices Screening: Upper endoscopy upon diagnosis of cirrhosis, and then every 1-3 years depending on findings.
  • Post-SVR for HCV Patients with Cirrhosis: Continue HCC and varices surveillance indefinitely due to residual risk, although the risk is significantly reduced.

Treatment Algorithms

Algorithms are complex and depend on specific guidelines (AASLD, EASL, etc.), patient factors (genotype, fibrosis stage, treatment experience, comorbidities), and local drug availability.

• First-Line (General Principles):
  • Chronic Hepatitis B: Entecavir or Tenofovir (TDF/TAF) for eligible patients.
  • Chronic Hepatitis C: Pangenotypic DAA regimens (e.g., glecaprevir/pibrentasvir or sofosbuvir/velpatasvir) are preferred for most patients.
• Second-Line:
  • Chronic Hepatitis B: Switching between ETV and TDF/TAF if initial treatment fails or resistance develops (rare with first-line agents).
  • Chronic Hepatitis C: For patients who fail initial DAA therapy (rare), retreatment typically involves a different DAA combination, often with ribavirin and/or for a longer duration (e.g., 16 weeks). Resistance testing may guide selection.
• Refractory Cases:
  • Chronic Hepatitis B: For patients with ongoing viral replication despite optimal NUC therapy, consider adherence issues, resistance (rare with current agents, but testing can confirm), or concurrent factors (e.g., alcohol). If resistance confirmed, switch to an agent with a different resistance profile.
  • Chronic Hepatitis C: True DAA failure is uncommon. Refer to a liver specialist. May involve consultation with a national/international resistance board, enrollment in clinical trials, or exploring transplant options if liver disease has progressed.

Complications

• Common:
  • Acute Hepatitis: Prolonged fatigue, post-hepatitis syndrome (mild, non-specific symptoms).
  • Chronic Hepatitis: Persistent inflammation, progressive fibrosis.
• Serious:
  • Cirrhosis: Irreversible scarring of the liver, leading to distorted architecture and impaired function.
  • Decompensated Cirrhosis: Development of complications indicative of severe liver dysfunction:
    • Ascites: Fluid accumulation in the peritoneal cavity.
    • Esophageal Varices: Dilated veins in the esophagus prone to rupture and severe bleeding.
    • Hepatic Encephalopathy: Neurological dysfunction due to accumulation of toxins normally cleared by the liver.
    • Spontaneous Bacterial Peritonitis (SBP): Infection of ascitic fluid without an obvious source.
    • Hepatorenal Syndrome (HRS): Functional renal failure in advanced liver disease.
    • Hepatopulmonary Syndrome: Hypoxemia due to pulmonary vascular dilations.
  • Hepatocellular Carcinoma (HCC): Primary liver cancer, a common complication of chronic HBV and HCV (even after SVR in HCV, though risk is reduced).
  • Fulminant Hepatic Failure: Rapidly progressive liver failure with encephalopathy and coagulopathy, high mortality.
• Long-term:
  • End-Stage Liver Disease (ESLD): Requiring liver transplantation.
  • Extrahepatic Manifestations: As listed in Clinical Presentation (e.g., cryoglobulinemia, glomerulonephritis, polyarteritis nodosa).
  • Psychological Impact: Anxiety, depression, stigma.

Prognosis

• Factors Affecting Outcome:
  • Viral Factors: Genotype (HCV), viral load, specific HBV mutations (e.g., pre-core/core promoter).
  • Host Factors: Age at infection (younger age of HBV acquisition increases chronicity risk), immune status, male sex, co-infection (e.g., HIV), obesity, metabolic syndrome, alcohol use, genetic predisposition.
  • Disease Stage at Diagnosis: Presence and severity of fibrosis/cirrhosis. Earlier diagnosis and treatment improve prognosis.
  • Response to Treatment: Achieving SVR in HCV, or sustained viral suppression in HBV, dramatically improves prognosis.
• Survival:
  • Acute Hepatitis A/E: Mortality is very low (<0.5%), except for FHF cases (up to 80% without transplant).
  • Acute Hepatitis B/C: Majority clear infection. Those who progress to chronic HBV/HCV face a 15-40% lifetime risk of developing cirrhosis, and 1-5% per year risk of HCC once cirrhotic.
  • Chronic HBV/HCV: Survival is significantly reduced in patients who progress to decompensated cirrhosis or HCC. Liver transplantation offers excellent long-term survival for those with ESLD.
  • HCV SVR: Achieving SVR for HCV significantly reduces all-cause mortality, liver-related mortality, and the risk of HCC (though it doesn't eliminate it in patients with established cirrhosis).
• Quality of Life: Significantly impaired in patients with chronic hepatitis, especially if progressive or complicated by cirrhosis. Successful antiviral treatment (HBV suppression, HCV SVR) improves physical and mental health, reducing fatigue and improving overall well-being.

Prevention

Primary

• Vaccination:
  • Hepatitis A Vaccine: Highly effective. Recommended for all children at 1 year of age, travelers to endemic areas, men who have sex with men (MSM), IV drug users, those with chronic liver disease, and occupational risk.
  • Hepatitis B Vaccine: Highly effective. Universal vaccination for all newborns, children, and adolescents. Also recommended for adults at high risk (healthcare workers, dialysis patients, IV drug users, MSM, multiple sexual partners, close contacts of infected individuals, chronic liver disease).
  • Hepatitis C/D/E: No approved vaccines available for general use (HEV vaccine available in China but not globally). HBV vaccine prevents HDV by preventing HBV infection.
• Safe Sex Practices: Consistent and correct use of condoms.
• Safe Injection Practices: For IV drug users: needle exchange programs, never sharing needles or drug paraphernalia.
• Blood Product Safety: Universal screening of donated blood, organs, and tissues for HBV, HCV, and HIV.
• Universal Precautions in Healthcare: Proper use of personal protective equipment (PPE), safe handling and disposal of sharps.
• Hygiene and Sanitation: Hand washing, safe food and water supply (especially for HAV, HEV).

Secondary

• Screening and Early Detection:
  • HCV Screening: One-time screening for all adults aged 18 and older. Repeat screening for individuals with ongoing risk factors. Screening for all pregnant women.
  • HBV Screening: Pregnant women (for perinatal prevention), individuals from high-prevalence regions, household contacts of HBV carriers, MSM, IV drug users, healthcare workers, hemodialysis patients, and HIV-infected persons.
  • Public Health Surveillance: Timely reporting of cases, contact tracing, and outbreak investigation.
• Post-Exposure Prophylaxis (PEP):
  • HBV: Hepatitis B Immune Globulin (HBIG) and HBV vaccine for significant exposures (e.g., needle stick, sexual contact, perinatal exposure from HBsAg-positive mother). Effectiveness is highest if given within 24-48 hours.
  • HAV: HAV vaccine and/or immune globulin (IG) for close contacts of confirmed HAV cases.
  • HCV: No approved PEP; monitor with HCV RNA at 3 and 6 months post-exposure.

Tertiary

• Treatment of Chronic Infection: Antiviral therapy to prevent progression to cirrhosis, HCC, and liver failure.
• Management of Complications: Regular surveillance for HCC (ultrasound/AFP), endoscopic screening for varices, management of ascites and encephalopathy.
• Liver Transplantation: For patients with end-stage liver disease or HCC who meet transplant criteria.

Special Populations

• Pediatric:
  • HBV: Most chronic HBV is acquired perinatally. Universal birth dose HBV vaccination is critical. Infants born to HBsAg-positive mothers should receive HBIG and HBV vaccine within 12 hours of birth. Treatment indications for CHB in children are narrower than adults, typically reserved for advanced fibrosis or active disease.
  • HCV: Perinatal transmission is the most common route. Spontaneous clearance occurs in 20-40% of children. DAAs are now approved for children as young as 3 years (e.g., sofosbuvir/ledipasvir, glecaprevir/pibrentasvir), with high SVR rates.
  • HAV: Often asymptomatic or mild. Vaccination is routine.
• Geriatric:
  • Increased risk of complications from acute hepatitis.
  • Higher prevalence of comorbidities and polypharmacy, requiring careful drug interaction assessment.
  • HCV treatment with DAAs is safe and highly effective in the elderly, similar to younger adults. Renal function and bone health should be monitored more closely with TDF.
• Pregnancy:
  • HBV: All pregnant women should be screened for HBsAg. High-viral-load mothers (HBV DNA >200,000 IU/mL or >6 log10 IU/mL) should be considered for antiviral therapy (e.g., TDF, generally started in the late second or early third trimester) to reduce perinatal transmission, in addition to passive-active immunoprophylaxis for the infant.
  • HCV: All pregnant women should be screened for HCV. No specific treatment for HCV recommended during pregnancy due to lack of DAA safety data, but treatment should be initiated post-partum. Breastfeeding is generally considered safe for HCV-positive mothers.
  • HAV/HEV: Most cases are self-limited. Pregnant women with acute HEV (especially genotype 1) are at higher risk of fulminant hepatic failure and mortality. HAV vaccine is safe during pregnancy if indicated.
• Comorbidities:
  • HIV Co-infection: Common, especially for HBV and HCV. Co-infected patients often have accelerated disease progression and poorer outcomes without treatment. DAA regimens for HCV are highly effective in HIV co-infected patients. HBV treatment often involves dual-active agents (e.g., TDF/TAF, lamivudine, emtricitabine) as part of antiretroviral therapy.
  • Renal Impairment/ESRD: Dosing adjustments for some antivirals may be needed (e.g., TDF dose reduction in severe renal impairment, though TAF requires no dose adjustment in any renal impairment; glecaprevir/pibrentasvir is safe in all stages including dialysis).
  • Liver Transplant Recipients: Management of recurrent HBV/HCV infection in the allograft. HBV recurrence is prevented with NUCs and HBIG. HCV recurrence is universal without treatment but is highly curable with DAAs.

Clinical Pearls

• Diagnostic:
  • "Acute hepatitis doesn't make chronic liver disease": While acute hepatitis can be severe, most liver damage leading to cirrhosis happens silently over years in chronic infection. Don't be falsely reassured by a resolved acute phase; subsequent chronic infection is the danger.
  • HCV screening for all adults: Important for identifying asymptomatic chronic infections before complications develop.
  • Rule out all causes of liver injury: Always consider drug-induced liver injury, autoimmune hepatitis, alcoholic liver disease, NAFLD, hemochromatosis, and alpha-1 antitrypsin deficiency when evaluating elevated LFTs.
  • ALT "flare" in chronic HBV: Can indicate immune clearance, but also potentially severe liver damage or reactivation. Monitor closely.
• Treatment:
  • HBV treatment is suppressive, not curative: Patients generally require long-term, possibly lifelong therapy. Counsel patients appropriately.
  • HCV treatment is curative: Achieving SVR means the virus is gone. However, patients with pre-existing cirrhosis still need HCC surveillance.
  • Adherence is key for DAAs: Missing doses can lead to treatment failure. Ensure patients understand the importance of adherence.
• Pitfalls:
  • Misinterpreting HBV serology: The combination of HBsAg, anti-HBc, anti-HBs is complex. Consult flowcharts or expert interpretation.
  • Missing HCC in cirrhotic patients: Regular 6-month surveillance is critical. HCC can develop even after HCV SVR or on HBV suppressive therapy.
  • Over-reliance on liver biopsy: Non-invasive methods (FibroScan, FIB-4) are generally sufficient for fibrosis staging.
  • Not screening for co-infections: HIV, other STIs should be considered.
  • Ignoring alcohol use: Even in viral hepatitis, alcohol significantly accelerates liver damage. Address alcohol abstinence strongly.
  • Forgetting about HDV: Always consider HDV in patients with chronic HBV, especially from endemic regions or with rapidly progressive disease.

Recent Updates

• Guidelines:
  • Universal HCV Screening: CDC and AASLD/IDSA now recommend one-time HCV screening for all adults aged ≥18 years (updated from birth cohort 1945-1965).
  • HBV Treatment: Continued emphasis on TAF and ETV as preferred first-line agents due to high potency and high barrier to resistance. Growing evidence supports "functional cure" for HBV (HBsAg loss) as a desirable but rare outcome.
  • HCV Treatment: Evolution to simpler, shorter duration (8-12 weeks), pangenotypic DAA regimens with very high SVR rates (e.g., glecaprevir/pibrentasvir, sofosbuvir/velpatasvir), making treatment accessible for nearly all patients regardless of genotype or prior treatment experience.
• Evidence:
  • Real-world effectiveness of DAAs: Large studies confirm the high efficacy and safety of DAAs observed in clinical trials, including in complex populations.
  • Impact of SVR on liver outcomes: Long-term follow-up data confirms that SVR significantly reduces the risk of HCC, liver decompensation, and mortality, even in patients with advanced fibrosis/cirrhosis (though the risk is not eliminated in those with cirrhosis).
  • New HBV agents in pipeline: Research continues on new therapeutic approaches for HBV, aiming for functional or complete cure, including host-targeting agents, immune modulators, and novel antivirals.
• Controversies:
  • Duration of HCC surveillance post-SVR: While risk is reduced, ongoing debate on whether and for how long HCC surveillance should continue in all patients with F3/F4 fibrosis at SVR.
  • Optimal management of HBV "inactive carriers": When to start treatment in patients with low HBV DNA and normal ALT, especially with mild fibrosis or family history of HCC.
  • Global elimination efforts: Challenges in reaching WHO hepatitis elimination targets by 2030, particularly regarding diagnosis rates and access to treatment in low-resource settings.

Key References

• Guidelines:
  • American Association for the Study of Liver Diseases (AASLD) & Infectious Diseases Society of America (IDSA): HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. (Online, regularly updated at www.hcvguidelines.org)
  • American Association for the Study of Liver Diseases (AASLD): Hepatitis B Guidance (Updated regularly, available via AASLD website).
  • European Association for the Study of the Liver (EASL): Clinical Practice Guidelines on the management of hepatitis B/C/D/E virus infection (Published in Journal of Hepatology, updated periodically).
  • Centers for Disease Control and Prevention (CDC): Viral Hepatitis Prevention and Control recommendations (www.cdc.gov/hepatitis).
• Studies:
  • Key DAA Trials: Studies like ION-1, ASTRAL-1, ENDURANCE, EXPEDITION (for HCV DAA regimens) which established efficacy and safety.
  • REVEAL Study (HBV): A landmark prospective cohort study demonstrating the natural history and risk factors for HCC in chronic HBV patients.
• Reviews:
  • Recent review articles in leading gastroenterology/hepatology journals (e.g., Gastroenterology, Hepatology, Journal of Hepatology, Gut) provide comprehensive summaries of current evidence and future directions.
  • Textbooks such as Sleisenger and Fordtran's Gastrointestinal and Liver Disease and Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases.